- Home
- RXT vs RGNX Comparison
RXT vs RGNX Comparison
Compare RXT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXT
- RGNX
- Stock Information
- Founded
- RXT 1998
- RGNX 2008
- Country
- RXT United States
- RGNX United States
- Employees
- RXT N/A
- RGNX N/A
- Industry
- RXT EDP Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXT Technology
- RGNX Health Care
- Exchange
- RXT Nasdaq
- RGNX Nasdaq
- Market Cap
- RXT 322.8M
- RGNX 387.0M
- IPO Year
- RXT 2020
- RGNX 2015
- Fundamental
- Price
- RXT $1.38
- RGNX $8.74
- Analyst Decision
- RXT Hold
- RGNX Strong Buy
- Analyst Count
- RXT 4
- RGNX 8
- Target Price
- RXT $1.63
- RGNX $31.75
- AVG Volume (30 Days)
- RXT 1.2M
- RGNX 1.0M
- Earning Date
- RXT 08-07-2025
- RGNX 07-31-2025
- Dividend Yield
- RXT N/A
- RGNX N/A
- EPS Growth
- RXT N/A
- RGNX N/A
- EPS
- RXT N/A
- RGNX N/A
- Revenue
- RXT $2,711,700,000.00
- RGNX $156,718,000.00
- Revenue This Year
- RXT N/A
- RGNX $327.08
- Revenue Next Year
- RXT $1.48
- RGNX N/A
- P/E Ratio
- RXT N/A
- RGNX N/A
- Revenue Growth
- RXT N/A
- RGNX 80.70
- 52 Week Low
- RXT $1.00
- RGNX $5.04
- 52 Week High
- RXT $3.41
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- RXT 59.20
- RGNX 49.54
- Support Level
- RXT $1.25
- RGNX $7.91
- Resistance Level
- RXT $1.38
- RGNX $8.99
- Average True Range (ATR)
- RXT 0.08
- RGNX 0.65
- MACD
- RXT 0.01
- RGNX -0.05
- Stochastic Oscillator
- RXT 84.62
- RGNX 37.70
About RXT Rackspace Technology Inc.
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.